Abstract Characterization of the genetic landscape of Alzheimer's disease (AD) and related
dementias (ADD) provides a unique opportunity for a better understanding of the associated …

Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and
together with polygenetic risk stratification can contribute towards planning of feasible and …

Objectives Mild behavioral impairment (MBI) is a syndrome describing late-onset persistent
neuropsychiatric symptoms (NPS) in non-demented older adults. Few studies to date have …

Objectives The core cerebrospinal fluid (CSF) biomarkers; total tau (tTau), phospho-tau
(pTau), amyloid β 1-42 (Aβ 1-42), and the Aβ 1-42/Aβ 1-40 ratio have transformed …

Background Mindfulness-based programs have shown a promising effect on several health
factors associated with increased risk of dementia and the conversion from mild cognitive …

Background: Assessing neuropsychiatric symptoms (NPS) in older adults is important for
determining dementia risk. Mild behavioral impairment (MBI) is an at-risk state for cognitive …

We previously demonstrated that serum levels of plasminogen activator inhibitor-1 (PAI-1),
which inhibits both the tissue plasminogen activator (tPA) and plasmin activity, are increased …

Background Spatial navigation impairment is a promising cognitive marker of Alzheimer's
disease (AD) that can reflect the underlying pathology. Objectives We assessed spatial …

Background There is initial evidence suggesting that biomarker neurogranin (Ng) may
distinguish Alzheimer's disease (AD) from other neurodegenerative diseases. Therefore, we …

Background Mild behavioral impairment (MBI) has been commonly reported in early
Alzheimer's disease (AD) but rarely using biomarker-defined samples. It is also unclear …